Switch to aflibercept in the treatment of neovascular AMD: One-year results in clinical practice

Ophthalmologica

Volumn 233, Issue , 2015, Pages 155-161

  Pinheiro Costa, João ^a   Costa, José M ^b   Beato, João N ^a   Freitas Da Costa, Paulo ^a   Brandão, Elisete ^a   Falcão, Manuel S ^a,b   Falcão Reis, Fernando ^a,b   Carneiro, Ângela M ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Aflibercept; Bevacizumab; Choroidal neovascularization; Ranibizumab; Switch; Wet age related macular degeneration

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL PRACTICE; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA HEMORRHAGE; RETINA TEAR; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG SUBSTITUTION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84930927133     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000381221     Document Type: Article

References (37)

1. Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM: Potential public health impact of Age-Related Eye Disease Study results: AREDS report No 11. Arch Ophthalmol 2003; 121: 1621-1624.
2. Klein R, Peto T, Bird A, Vannewkirk MR: The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-495.
3. Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111-118.
4. Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonca LS, Fonseca SL, Goncalves R, Goncalves C, Falcao-Reis FM, Soares R: Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012; 90:e25-e30.
5. Stewart MW: Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol 2012; 6: 1175-1186.
6. Andreoli CM, Miller JW: Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18: 502-508.
7. Carneiro AM, Falcao MS, Brandao EM, Falcao-Reis FM: Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina 2010; 30: 85-92.
8. Meyer CH, Holz FG: Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011; 25: 661-672.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.e55.
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
11. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
12. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
13. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
14. Carneiro AM, Mendonca LS, Falcao MS, Fonseca SL, Brandao EM, Falcao-Reis FM: Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol 2012; 6: 1149-1157.
15. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN: Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 2008; 145: 249-256.
16. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
17. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, Walsh AC, Hwang J, Sadda SR: Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012; 96: 14-20.
18. Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR: Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3115-3120.
19. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22.e1.
20. Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S: Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 2013; 97: 1443-1446.
21. Eghoj MS, Sorensen TL: Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96: 21-23.
22. Schaal S, Kaplan HJ, Tezel TH: Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in agerelated macular degeneration? Ophthalmology 2008; 115: 2199-2205.
23. Binder S: Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012; 96: 1-2.
24. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT: Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29: 723-731.
25. Stewart MW: Aflibercept (VEGF Trap-eye): The newest anti-VEGF drug. Br J Ophthalmol 2012; 96: 1157-1158.
26. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
27. Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C: Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther 2013; 7: 711-722.
28. Stewart MW, Rosenfeld PJ: Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667-668.
29. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U: Intravitreal aflibercept (VEGF Trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
30. Cho H, Shah CP, Weber M, Heier JS: Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-1035.
31. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB: Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612.
32. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd: Short-term outcomes of aflibercept for neovascular agerelated macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013; 156: 23-28.e2.
33. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK: Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29-35.e2.
34. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG: Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond) 2014; 28: 895-899.
35. Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, Flaxel CJ, Hwang TS: Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular agerelated macular degeneration. Br J Ophthalmol 2014; 98: 1205-1207.
36. Fassnacht-Riederle H, Becker M, Graf N, Michels S: Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1705-1709.
37. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M: Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014; 121: 188-192.